SCYB.V - Scythian Biosciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
3.49
0.00 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.49
Open3.71
Bid2.60 x 0
Ask2.60 x 0
Day's Range3.46 - 3.77
52 Week Range1.01 - 8.61
Volume703,166
Avg. Volume164,420
Market Cap103.247M
Beta4.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • CNW Group7 hours ago

    IIROC Trade Resumption - SCYB

    IIROC Trade Resumption - SCYB

  • GlobeNewswire7 days ago

    Scythian Biosciences Announces Licencing of Colcanna SAS to Cultivate and Import THC into Colombia

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl: SCCYF)  is pleased to announce that Colombian-based Colcanna SAS (“Colcanna”), has received a licence for the cultivation and importation of Tetrahydrocannabinol (“THC”) by the Ministry of Justice and Law of Colombia. With this additional licence, Colcanna is now authorized to cultivate, import, extract and produce THC, as well as cannabidiol – two of the main constituents of cannabis. Additionally, MMJ Colombia Partners, a privately-held Ontario company, has completed its acquisition of 90% of Colcanna SAS.

  • GlobeNewswire14 days ago

    Scythian Invests in PRØHBTD, a Leading Global Cannabis Media Platform

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl: SCCYF) today announced it has invested in and entered into a strategic partnership with PRØHBTD Media, Inc, a leading global cannabis media and brand platform. PRØHBTD has built a first-of-its-kind cannabis ecosystem that includes a brand creation and product development platform, complemented by an original content studio and the first and largest multi-platform video network in the cannabis industry. In addition to the company’s flagship lifestyle destination www.prohbtd.com, video content is syndicated across 15 different partner platforms, including Apple TV, Roku, Amazon, Android TV, Dailymotion and others, which saw more than 22 million video views in June, with an average view-through rate of 3:47 minutes.

  • GlobeNewswire16 days ago

    Scythian Biosciences to Acquire Company with Exclusive Medical Cannabis License in Florida

    Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced it has signed an arm’s length letter of intent effective July 26, 2018 to acquire CannCure Investments Inc. (“CannCure”).

  • GlobeNewswire20 days ago

    Scythian Biosciences Announces Director Resignation

    Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced that Mr. George Scorsis has resigned from its board of directors, and that Rob Reid has been appointed Interim Chairman. George Scorsis said: “It’s been a great pleasure to help guide Scythian on its journey to becoming the global cannabis player it is today, and I have no doubt the company will continue to make great strides in its research and expansion efforts.

  • CNW Group20 days ago

    IIROC Trading Halt - SCYB

    IIROC Trading Halt - SCYB

  • GlobeNewswire21 days ago

    Scythian Chief Medical Officer Professor Michael Barnes Expands Global Influence as a Cannabis Key Opinion Leader

    Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced that its Chief Medical Officer, Professor Michael Barnes, is rapidly expanding his international strategy and influential reach. Professor Barnes, MD, FRCP, is a leading world authority in neurological rehabilitation and has emerged as an influential voice in medical cannabis policy in Europe.

  • GlobeNewswire23 days ago

    Scythian Biosciences Corp. Announces Strategic Partnership for Cannabis in Brazil with one of the Founders of the Country’s Pharma Industry

    Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is thrilled to announce its Brazilian partnership with Green Farma Brasil of Sao Paulo. The partnership will be managed by Brazilian Pharmaceutical veteran, Adalmiro Dellape Baptista Junior (“Adalmiro”), the son of Aché Pharmaceutical Laboratories (“Group Aché”) founder, Brazil’s third largest pharmaceutical companies.  Adalmiro has devoted more than 30 years of his life to the pharmaceutical industry and has experience in all areas of the Brazilian market.

  • GlobeNewswire29 days ago

    Scythian Announces Strategic Sale of Latin American and Caribbean Assets in $193,000,000 Deal to Aphria

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that it has entered into a strategic deal with Aphria Inc. It is expected that the Company’s strategic relationship with Aphria will provide leverage for early stage investments in emerging international markets.

  • GlobeNewswirelast month

    Scythian Biosciences Announces Positive Pre-Clinical Data on the Safety and Efficacy of Cannabis Derived Combination Therapy for Mild to Moderate Traumatic Brain Injury

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) and its partners at the University of Miami Miller School of Medicine are pleased to announce the results of a pre-clinical study evaluating the safety and efficacy of a cannabis derived combination therapy in the treatment of mild to moderate traumatic brain injury (TBI) in rodents. The pilot study indicates an improvement in the cognitive functions of animals treated with a cannabinoid (CBD) derived combination therapy compared to being treated with a vehicle, CBD alone, and HU211 alone. Further, there were no adverse effects from either the combination therapy (CBD + HU211) or the individual components observed by scientists at the University of Miami Miller School of Medicine.

  • GlobeNewswirelast month

    Scythian Biosciences Corp Announces Colcanna SAS as one of the Industry’s First to Receive Key Cannabis Licences for the Cultivation, Extraction, Production and Research of Medical Cannabis for the Colombian Local Market and Export to International Markets

    TORONTO, July 09, 2018-- Scythian Biosciences Corp. is pleased to announce that Colombian-based Colcanna SAS, the pending acquisition by Scythian, has received additional licences by the Ministry of Health ...

  • GlobeNewswire2 months ago

    Grit Capital launches GritCAMP Immersive Investment Conference in Muskoka July 25-27th 2018

    Grit Updates the Market on Recent Corporate Initiatives & Milestones. TORONTO, June 22, 2018-- GRIT CAPITAL INC. a capital markets advisory firm known for its aggressive“ out of the box” thinking to capture ...

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Name Change to SOL Global Investments Corp.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that the Company will be changing its name from “Scythian Biosciences Corp.” to “SOL Global Investments Corp.” The Company will put the name change resolution before its shareholders at its next scheduled annual general meeting, which will be sometime in August 2018. The name change is also subject to approval by the TSX Venture Exchange (“TSXV”).

  • CNW Group4 months ago

    IIROC Trading Halt - SCYB

    IIROC Trading Halt - SCYB

  • CNW Group4 months ago

    IIROC Trading Resumption - SCYB

    IIROC Trading Resumption - SCYB